SomnoMed Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

SomnoMed hat ein Gesamteigenkapital von A$45.0M und eine Gesamtverschuldung von A$1.0M, was einen Verschuldungsgrad von 2.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen A$69.8M bzw. A$24.8M.

Wichtige Informationen

2.3%

Verhältnis von Schulden zu Eigenkapital

AU$1.02m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	AU$16.18m
Eigenkapital	AU$45.02m
Gesamtverbindlichkeiten	AU$24.78m
Gesamtvermögen	AU$69.80m

Jüngste Berichte zur Finanzlage

Recent updates

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

Oct 16

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Mar 04

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

Dec 21

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Sep 02

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Jun 19

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SOMDie kurzfristigen Aktiva des Unternehmens (A$35.1M) übersteigen seine kurzfristigen Passiva (A$19.9M).

Langfristige Verbindlichkeiten: SOMDie kurzfristigen Vermögenswerte des Unternehmens (A$35.1M) übersteigen seine langfristigen Verbindlichkeiten (A$4.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SOM über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SOM Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 16.9% auf 2.3% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: SOM auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: SOM verfügt über eine ausreichende Liquiditätsreserve für 1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 13.2% pro Jahr abnimmt.

SomnoMed Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Is SomnoMed (ASX:SOM) Using Too Much Debt?

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Recent updates

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited Announces Board Changes

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

SomnoMed Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45

Full year earnings released - AU$0.0069 loss per share

New 90-day high: AU$2.14

Chairman of the Board recently bought AU$203k worth of stock

New 90-day high - AU$1.58